Aclaris Therapeutics Q1 2025 Earnings Report

Aclaris Therapeutics EPS Results

• Actual EPS: -$0.12
• Consensus EPS: -$0.19
• Beat/Miss: Beat by +$0.07
• One Year Ago EPS: N/A

Aclaris Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $3.55 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Aclaris Therapeutics Announcement Details

• Quarter: Q1 2025
• Date: 5/6/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, May 8, 2025
• Conference Call Time: 7:00AM ET

Aclaris Therapeutics (NASDAQ:ACRS) (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates. The company’s development strategy emphasizes both topical and oral small molecules that aim to provide targeted modulation of immune pathways with favorable safety and tolerability profiles.

Aclaris’s clinical programs span Phase 2 and Phase 3 trials, supported by strategic interactions with regulatory authorities and collaborations with diagnostic and academic partners. While the company currently focuses on patient populations in the United States, it maintains a framework for future expansion into select international markets through licensing arrangements and strategic alliances.

The leadership team is headed by Chief Executive Officer Adam Gould, whose background includes extensive experience in dermatology drug development and regulatory affairs. Supported by a board of directors with deep expertise in pharmaceutical research, clinical operations and commercialization, Aclaris is positioned to advance its late‐stage pipeline toward potential approval and market launch.